Dr. Chappell worked with the GLP-1 receptor analogues since the first one, exenatide, appeared nearly 20 years ago. Derived from the saliva of Gila monsters, exenatide was marketed as Byetta in 2005 and had to be taken twice a day.

Five years later liraglutide was developed and marketed as Victoza, which was released in 2010 as the once daily predecessor of the now very popular and successful semaglutide (Ozempic), which is taken once weekly and FDA-approved in 2017.

Victoza and Ozempic are GLP-1 receptor analogues that are FDA-approved for treatment of type 2 diabetes. There are other once-weekly GLP-1 receptor analogues as well. GLP-1 is a normal, short-lived gut hormone released in response to nutrient flux in the distal small intestine. Both have excellent safety and efficacy record.

In 2022, tirzepatide (Mounjaro) appeared with dual modes of action, namely, both GLP-1 and GIP receptor action. GIP is another short-lived, gut hormone. Mounjaro outperformed Ozempic in one head-to-head trial.

For obesity treatment, liraglutide and semaglutide have been marketed as Saxenda and Wegovy, respectively. FDA approval for tirzepatde to treat obesity is in progress.

Dr. Chappell has been using these drugs since their appearance in the world of endocrinology in 2005. As a pharmaceutical educator, he taught local physicians on their use, safety, and efficacy. He has treated hundreds of patients with Victoza, Ozempic, and Mounjaro.

Many people are using liraglutide, semaglutide, and tirzepatide in unsupervised or under-supervised settings. This could be dangerous. Wouldn’t you rather work with an endocrinologist that has many years of experience and up-to-date knowledge on diabetes and weight loss?

IHM offers Free Orientations to learn more about our successful weight loss program. New clients will receive 10 percent off our fasting fee for the first month.
Request An Appointment